title: Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
authors.affiliation: Universitäts-Frauenklinik Frankfurt, German Breast Group Forschungs GmbH, Martin-Behaim-Strasse 12, 63263 Neu-Isenburg, Germany. Gunter.vonminckwitz@germanbreastgroup.de
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.forename: Mahdi
authors.initials: M
authors.lastname: Rezai
authors.forename: Sibylle
authors.initials: S
authors.lastname: Loibl
authors.forename: Peter A
authors.initials: PA
authors.lastname: Fasching
authors.forename: Jens
authors.initials: J
authors.lastname: Huober
authors.forename: Hans
authors.initials: H
authors.lastname: Tesch
authors.forename: Ingo
authors.initials: I
authors.lastname: Bauerfeind
authors.forename: Jörn
authors.initials: J
authors.lastname: Hilfrich
authors.forename: Holger
authors.initials: H
authors.lastname: Eidtmann
authors.forename: Bernd
authors.initials: B
authors.lastname: Gerber
authors.forename: Claus
authors.initials: C
authors.lastname: Hanusch
authors.forename: Thorsten
authors.initials: T
authors.lastname: Kühn
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
authors.forename: Jens-Uwe
authors.initials: JU
authors.lastname: Blohmer
authors.forename: Christoph
authors.initials: C
authors.lastname: Thomssen
authors.forename: Serban
authors.initials: S
authors.lastname: Dan Costa
authors.forename: Christian
authors.initials: C
authors.lastname: Jackisch
authors.forename: Manfred
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Keyur
authors.initials: K
authors.lastname: Mehta
authors.forename: Michael
authors.initials: M
authors.lastname: Untch
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005858:Germany; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010349:Patient Compliance; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D003520:Cyclophosphamide; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human